San Francisco, CANCT05396872Now EnrollingIRB Ready

Prostate Cancer Clinical Trial in San Francisco, CA

Access cutting-edge prostate cancer treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Francisco

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related prostate cancer treatment provided free

Apply for This San Francisco Location

Check if you qualify for this prostate cancer clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Prostate Cancer Study in San Francisco

This clinical trial explores and implements methods to improve informed decision making (IDM) regarding precision oncology tests amongst veterans with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Precision oncology, the use of germline genetic testing and tumor-based molecular assays to inform cancer care, has become an important aspect of evidence-based care for men with advanced prostate cancer. Veterans with metastatic castrate-resistant prostate cancer may not be carrying out IDM due to unmet decisional needs. An informed decision is a choice based on complete and accurate information. The information gained from this study will help researchers develop a decision support intervention (DSI) and implement the intervention. A DSI may serve as a valuable tool to reduce ongoing racial disparities in genetic testing and encourage enrollment to precision oncology trials.

Sponsor: University of California, San Francisco

Who Can Participate

Inclusion Criteria

Patient-participants:
Age 18 years or older.
Able to understand study procedures and to comply with them for the entire length of the study.
Able to understand a written informed consent document and willing to sign it.
Able to speak, read, and understand English.
Documentation of locally advanced (pelvic lymph node-positive), metastatic, or castration-resistant prostate cancer in a clinical progress note or pathology report.
Scheduled to attend a hematology/oncology appointment (in person or remote) during which provider anticipates discussing germline testing, somatic tumor testing, or targeted therapy. Caregiver-participants:
Age 18 years or older.
Identified by a patient-participant as an individual who is involved with the patient's care, and willing to join the interviews.
Able to provide verbal consent.
Able to speak and understand English. Provider-participants:
Hematology/oncology or Genetics provider (medical doctor (MD) or nurse practitioner (NP), post-first year clinical fellows allowed).
Has discussed germline testing, somatic testing, or targeted therapy for an San Francisco Veteran Health Care System (SFVAHCS) patient with locally advanced or metastatic prostate cancer (as defined above) within the past 90 days of being contacted about the study.
Able to provide consent via email. Stage 2: Inclusion Criteria: Patient participants:
Participated in Stage 1.
Completed either germline or tumor testing for prostate cancer.
Able to understand study procedures and to comply with them for the entire length of the study. Caregiver-participants:
Participated in Stage 1.
Partner, family-member, or friend of a Stage 2 participant (identified by the patient-participant as a caregiver). SFVAHCS Provider-participants:
Participated in Stage 1.
Meets one of the two following criteria:
Physician specializing in medical oncology (MD, post-first year clinical fellows allowed) who has discussed genetic testing or targeted therapy with a patient with advanced prostate cancer within the past 30 days of being contacted for this study.
Physician specializing in genetics who has discussed genetic testing or targeted therapy with a patient with advanced prostate cancer within the past 90 days of being contacted for this study. Non-SFVAHCS provider-participants:
Meets one of the three following criteria:
Principal investigator of a Precision Oncology Program for Cancer of the Prostate (POPCaP) site.
Physician specializing in medical oncology who has discussed genetic testing or targeted therapy with a patient with advanced prostate cancer within the past 30 days of being contacted for this study.
Physician specializing in genetics who has discussed genetic testing or targeted therapy with a patient with advanced prostate cancer within the past 90 days of being contacted for this study. Note: For Non-SFVAHCS providers, fellows are not eligible.
Able to understand study procedures and to comply with them for the entire length of the study. Stage 3: Inclusion Criteria Patient-participants
Age 18 years or older.
Able to understand study procedures and to comply with them for the entire length of the study.
Able to understand a written informed consent document and willing to sign it.
Able to speak, read, and understand English.
Documentation of high-risk localized, very high-risk localized, locally advanced (pelvic lymph node-positive), metastatic, or castration-resistant prostate cancer in a clinical progress note or pathology report.
Scheduled to attend a hematology/oncology appointment (in person or remote) during which provider anticipates discussing germline testing. Caregiver-participants
Age 18 years or older.
Identified by a patient-participant as an individual who is involved with the patient's care, and willing to join the interview.
Able to provide verbal consent.
Able to speak and understand English. Provider-participants
SFVAHCS physician (MD) trained in medical oncology or undergoing training as a clinical fellow.
Has discussed germline testing for prostate cancer with an SFVAHCS patient within the past year of being contacted about the study, or plans to discuss germline testing for prostate cancer with an SFVAHCS patient.
Able to provide verbal consent. Stage 1:

Exclusion Criteria

Patient-participants:
For patient-participants undergoing genetic testing, if results of the genetic tests have already been disclosed to the participant, they are not eligible. Caregiver and Provider-Participants
If they do not meet any of the inclusion criteria above. Stage 2: Exclusion Criteria 1\. Participants who do not meet the inclusion criteria above. Stage 3: Exclusion Criteria Patient-participants:
Prior receipt of germline testing.
Prior participation in Stage 1 for germline testing. Caregiver and Provider-Participants 1\. If they do not meet any of the inclusion criteria above.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT05396872) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Cancer Treatment Options in San Francisco, CA

If you're searching for prostate cancer treatment options in San Francisco, CA, this clinical trial (NCT05396872) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in San Francisco, CA

See all prostate cancer clinical trials recruiting in San Francisco — not just this study.

Browse Prostate Cancer Trials in San Francisco →

Browse More Trials by Condition

Prostate Cancer TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA